Wall Street Zen Upgrades Precipio (NASDAQ:PRPO) to “Buy”

Precipio (NASDAQ:PRPO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Precipio Price Performance

NASDAQ:PRPO opened at $26.86 on Friday. Precipio has a one year low of $3.90 and a one year high of $29.53. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. The stock has a market cap of $47.01 million, a PE ratio of -32.76 and a beta of 1.22. The stock has a 50 day moving average price of $24.21 and a 200 day moving average price of $22.04.

Institutional Trading of Precipio

Several hedge funds have recently made changes to their positions in PRPO. Susquehanna International Group LLP acquired a new stake in shares of Precipio during the 3rd quarter worth approximately $194,000. Renaissance Technologies LLC lifted its holdings in Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the last quarter. Evernest Financial Advisors LLC purchased a new position in Precipio in the third quarter worth approximately $374,000. Geode Capital Management LLC grew its position in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the period. Finally, Topline Capital Management LLC acquired a new stake in Precipio during the third quarter worth $1,158,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.